Duodenal and cutaneous metastases from rectal cancer are rare and associated with poor prognosis. This case report describes a patient with advanced rectal cancer who developed these uncommon metastases after first-line therapy. Upon treatment with fruquintinib, the patient experienced a rapid and significant regression of the cutaneous lesions, demonstrating a visible clinical response. This suggests that fruquintinib may be an effective therapeutic option for patients with such aggressive and rare metastatic disease.
He et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: